APOE ε2
E1405304
UNEXPLORED
APOE ε2 is a common apolipoprotein E gene variant associated with a reduced risk of late-onset Alzheimer’s disease but an increased risk of type III hyperlipoproteinemia.
All labels observed (1)
| Label | Occurrences |
|---|---|
| APOE ε2 canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T19992621 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: APOE ε2 Context triple: [APOE gene, hasAllele, APOE ε2]
-
A.
APOE ε3 allele
The APOE ε3 allele is the most common and generally considered the “neutral” variant of the apolipoprotein E gene, associated with average risk for Alzheimer’s disease and typical lipid metabolism compared to other APOE alleles.
-
B.
APOE ε4 allele
The APOE ε4 allele is a genetic variant of the apolipoprotein E gene that significantly increases an individual's susceptibility to late-onset Alzheimer's disease.
-
C.
APOE gene
The APOE gene encodes apolipoprotein E, a key protein in lipid metabolism whose variants, especially ε4, strongly influence risk for Alzheimer’s disease and cardiovascular disorders.
-
D.
EPAS1
EPAS1 is a human gene encoding a hypoxia-inducible transcription factor that plays a key role in adaptation to low-oxygen environments, notably implicated in high-altitude tolerance.
-
E.
CYP3A5
CYP3A5 is a liver-expressed cytochrome P450 enzyme that metabolizes various drugs and xenobiotics, contributing to interindividual variability in drug clearance.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: APOE ε2 Target entity description: APOE ε2 is a common apolipoprotein E gene variant associated with a reduced risk of late-onset Alzheimer’s disease but an increased risk of type III hyperlipoproteinemia.
-
A.
APOE ε3 allele
The APOE ε3 allele is the most common and generally considered the “neutral” variant of the apolipoprotein E gene, associated with average risk for Alzheimer’s disease and typical lipid metabolism compared to other APOE alleles.
-
B.
APOE ε4 allele
The APOE ε4 allele is a genetic variant of the apolipoprotein E gene that significantly increases an individual's susceptibility to late-onset Alzheimer's disease.
-
C.
APOE gene
The APOE gene encodes apolipoprotein E, a key protein in lipid metabolism whose variants, especially ε4, strongly influence risk for Alzheimer’s disease and cardiovascular disorders.
-
D.
EPAS1
EPAS1 is a human gene encoding a hypoxia-inducible transcription factor that plays a key role in adaptation to low-oxygen environments, notably implicated in high-altitude tolerance.
-
E.
CYP3A5
CYP3A5 is a liver-expressed cytochrome P450 enzyme that metabolizes various drugs and xenobiotics, contributing to interindividual variability in drug clearance.
- F. None of above. chosen
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.